Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, which selectively induces apoptosis in many transformed cells without apparent toxic side effects in normal tissue. We recently described the construction and characterization of a lentiviral vector for expression of TRAIL. In this report, we evaluate its suitability for therapeutic application. In vitro, we observed specific induction of apoptosis upon transduction in human lung cancer cells. Cell death was partially dependent on successful integration and TRAIL expression by the vectors, but was to some extent mediated by protein carryover, as we found TRAIL protein associated with virus particles. Transduction of subcutaneously growing lung tumors on nude mice with lentiviral TRAIL mediated a transient suppression of tumor growth. Analysis of tumor sections revealed that transduction efficiency of lentiviral control vector but not of lentiviral TRAIL vector was high. This was because of the direct cytotoxic activity of recombinant TRAIL present in viral particles, which prevented efficient tumor transduction. These data therefore suggest that enveloped viral vectors constitutively expressing TRAIL are well suited for ex vivo applications, such as the transduction of tumorhoming cells, but may have a lower effect when used directly for the transduction of tumor cells in vivo.
Introduction
The death ligand tumor necrosis factor-related apoptosisinducing ligand (TRAIL) (Apo2L) has become a promising candidate for cancer therapy because of its unique ability to induce apoptosis specifically in transformed cells, while sparing most normal cells. 1 TRAIL induces apoptosis via the two TRAIL death receptors, TRAILreceptor 1 (TRAIL-R1, also known as death receptor 4, DR4) and TRAIL-receptor 2 (TRAIL-R2, also known as DR5). 2 Upon engagement by the ligand, the TRAIL death receptors oligomerize and form a death inducing signaling complex (DISC) by recruiting FADD, caspase-8 and -10, and FLIP. 3 At the DISC, caspase-8 is autocatalytically activated. Further caspases are either directly cleaved and activated by caspase-8 or by Bidmediated engagement of the mitochondrial apoptosis pathway. 4 The antitumor activity of a variety of recombinant TRAIL protein versions or agonistic antibodies has been shown in a number of preclinical in vitro and in vivo models. [5] [6] [7] Although apoptosis induction in non-malignant human hepatocytes by TRAIL is described, this unwanted TRAIL effect seems to be mainly because of aberrant or too strong receptor crosslinking by certain variants of recombinant TRAIL or agonistic antibodies. 8, 9 Nevertheless, for the therapy of solid, localized tumors, approaches to reach maximal intratumoral TRAIL levels, although keeping the systemic levels as low as possible, are desirable to avoid any side effects of TRAIL to normal tissue.
Approaches to cancer gene therapy have featured the transfer of numerous therapeutic genes and utilizing several different gene transfer systems. [10] [11] [12] [13] [14] As attempts using prodrug-activating suicide genes or overexpression of tumor suppressor genes suffered from insufficient in vivo transduction rates, approaches leading to strong bystander killing of untransduced cells are important for successful cancer therapy. Recent studies describe TRAIL gene therapy approaches by using adenoviral or AAV vectors which have been found to suppress tumor growth in vivo using xenografted mice. [15] [16] [17] Also, refined versions of adenoviral vectors expressing TRAIL under the transcriptional control of tumor-specific regulatory elements have been proposed as effective antitumor agents. 18, 19 Moreover, the application of TRAIL expressing cells into tumor-bearing mice, for example, by TRAIL overexpressing neural stem cells or Tet-inducible T cells achieved local production of TRAIL followed by apoptosis. 20, 21 However, viral gene transfer using adenoviral or AAV-vectors is only capable of transient gene expression, resulting in the outgrowth of tumors after loss of transgene expression in most cases. HIV-derived VSV-G-pseudotyped lentiviral vectors may overcome this obstacle as they provide efficient gene transfer and are demonstrated to mediate stable, high-level transgene expression both in vitro and in vivo. 22, 23 Therefore, we recently constructed and described a lentiviral vector expressing TRAIL. 24 We observed the induction of apoptosis in a B-cell lymphoma line in vitro both by TRAIL expressed upon transduction and by direct action of TRAIL protein associated with viral particles. We could show that full-length TRAIL, but not soluble TRAIL, was produced by packaging cells after transfection and target cells upon transduction, and that fulllength TRAIL was associated with viral particles. This recent study however was mainly focused on a novel mechanism by which cells acquire resistance towards TRAIL by permanent overexpression of this death ligand.
Here, we investigated the therapeutic potential of lentiviral TRAIL gene transfer in vivo, using NSCLC cells as a model system. We quantitatively analyzed gene transfer and apoptosis induction upon transduction, and the role of TRAIL protein carryover in vitro. Upon transduction of xenografted tumors, we observed a transient growth delay. However, tumors transduced with lentiviral TRAIL started to grew as fast as control cells 3 days after transduction. Analysis of cryosections revealed efficient tumor transduction with the control lentiviral construct, but weak transduction with the specific TRAIL construct. Although we detected transduction-dependent induction of apoptosis in tumor cells mediated by membrane-bound TRAIL, we could show that the weak transduction efficiency was mediated by fast induction of apoptosis in transduced tumor cells due to the direct cytotoxic activity of recombinant TRAIL present in viral particles. Thus, passively transferred recombinant TRAIL protein was responsible for transduction-independent induction of apoptosis by lentiviral TRAIL. These data suggest that lentiviral TRAIL gene transfer may be an efficient strategy to induce fast apoptosis in tumor cells in vitro whereas the therapeutic effect in vivo is impeded by the TRAIL protein carryover.
Materials and methods
Cell culture P693 non-small-cell lung cancer, 25 and HEK 293T 26 cells were cultured in Dulbecco's modified Eagles medium (DMEM) (PAA, Pasching, Austria), supplemented with 10% heat-inactivated fetal calf serum (Sigma, Deisenhofen, Germany), 2 mM L-glutamine (PAA), 10 mM N-2-hydroxyethylpierazine-N 0 -2-ethanesulfonic acid (PAA) and 2.5 mg/ ml plasmocin (InvivoGen, San Diego). For virus production, DMEM with 4 mM L-glutamine was used. Cells were cultured at 371C and 5% CO 2 . Antibodies used were mouse monoclonal anti-TRAIL  2E5 and anti-TRAIL-R1, -R2, -R3 and -R4 (HS101, HS  201, HS 301 and HS401 , Alexis, Gru¨nberg, Germany), anti-cytokeratin-18 (cleaved form, clone M30, Roche, Mannheim, Germany), unspecific control antibody (MOPC 21, Sigma, Deisenhofen, Germany), anti-mouseIgG-AlexaFluor547 secondary antibody (Molecular Probes, Eugene, OR), anti-mouse-IgG-biotin and streptavidin-APC (Becton-Dickinson, Heidelberg, Germany) and anti-mouse IgG-HRP (SantaCruz, Heidelberg, Germany). FLAG-TRAIL and TRAIL-R2-Fc protein have been described. 3, 27 All other chemicals were from Sigma or Carl Roth (Karlsruhe, Germany).
Antibodies and reagents
Transfection, virus preparation and titer determination Construction of the used lentivirus plasmids is described in our recent publication. 24 Vector stocks were produced according to previously described protocols, 28 Transduction of cultured cells P693 cells were seeded in six-well plates at 5 Â 10 5 cells per well in 2 ml complete medium containing 4 mg/ml polybrene and virus was added. AZT was used at 5 mg/ml. The plates were centrifuged at 1200 r.p.m., 321C for 1 h and incubated at 371C. Medium was replaced by fresh medium after 6-16 h.
Measurement of apoptosis and flow cytometry Apoptosis was measured by flow cytometry using the Nicoletti method to determine the DNA content of cells and the sub-G1 population, 30 or by staining with annexinV as described earlier. 31 Experiments were performed at least three times in triplicate and values given are the mean of triplicates7standard deviation. Surface stainings of TRAIL receptors were carried out as described, 24 except that biotinylated anti-mouse-IgG and streptavidin-APC were used according to the manufacturer's recommendations. Dead cells were excluded by propidium iodide staining.
TRAIL ELISA Enzyme-linked immunosorbent assay (ELISA) plates were coated with TRAIL-R2-Fc (0.4 mg/ml) and blocked with BSA (10 mg/ml). TRAIL was detected using the anti-TRAIL monoclonal antibody 2E5 (0.5 mg/ml), anti-mouse IgG-HRP and OPD/H 2 O 2 . Optical density (OD) was measured using an ELISA reader at 490 nm. Background values, obtained using fresh cell culture medium, were subtracted from OD values. All measurements were carried out in triplicates at least twice.
Animal experiments P693 cells (2.5 Â 10 6 cells in 100 ml PBS) were injected s.c. into the subaxillar region of 6À10-week-old BALBc (nu/nu) female mice, which were maintained in pathogenfree isolators. After 2 days, lentiviral in 50 ml PBS containing 0.1% BSA and 4 mg/ml polybrene were injected into the tumor. The tumor growth was followed by measuring two diameters with calipers. The tumor volume was calculated by the formula V ¼ (a 2 Â b)/2, where a is the width and b the length in mm. Two animals per group were killed after 3 days, the remaining eight animals per group were killed 12 days after LV injection, followed by excision of tumors. Statistical analysis was carried out using the Wilcoxon rank sum test. All animal experiments have been carried out with ethical committee approval.
Cryosections and immunofluorescence
Tumors were fixed in 4% PFA for 16 h at 41C and postfixed in 30% sucrose for at least 24 h at 41C. Sections (8 mm) of Tissue-Tek-embedded (Sakura, Zoeterwoude, The Netherlands) tumors were prepared. The slides were incubated with primary antibody (10 mg/ml) for 1 h, washed and incubated with secondary antibody (1:250) for 1 h, washed again, mounted in Fluoromount G (Southern Biotech, Birmingham, AL) and examined by fluorescence microscopy (Nikon, Du¨sseldorf, Germany).
Results
Transduction-dependent and -independent induction of apoptosis by LV-TRAIL To determine the in vitro antitumor efficacy of TRAIL gene transfer, we transduced the NSCLC cell line P693 with a lentiviral vector (LV) co-expressing TRAIL and GFP (LV-TRAIL) or GFP alone (LV-GFP). These cells are moderately TRAIL sensitive, requiring incubation with 50-500 ng/ml recombinant TRAIL for 24-48 h for substantial induction of apoptosis (data not shown). We measured apoptosis 3 days post-transduction with lentiviral TRAIL. Transduction with LV-TRAIL resulted in a level of about 40% apoptosis, whereas transduction with LV-GFP did not induce apoptosis ( Figure 1a ). Transduction in the presence of the reverse transcriptase blocker AZT lowered TRAIL-induced apoptosis to 30%, but did not completely abolish it. As we have recently shown, LV-TRAIL particles contain the membrane-bound 42 kDa form of TRAIL, which is expressed in the 293 T producer cells upon transfection. 24 Thus, the residual apoptosis may be due to the TRAIL protein present in the viral particles, or due to the ability of AZT to sensitize for TRAIL-induced apoptosis, 32 or a combination of both. As both constructs express the marker gene GFP, we could measure the transduction efficiency of each construct by FACS analysis of GFP expression ( Figure 1b) . We found that GFP expression was slightly higher in LV-TRAIL-transduced cells than in the LV-GFP-transduced cells, both in the presence and absence of AZT. In the presence of AZT, GFP expression was completely abolished in LV-GFP-transduced cells and almost completely abolished in LV-TRAIL-transduced cells. This might be due to the fact that the transduced cell 
Lentiviral TRAIL tumor therapy
T Wenger et al population, which is not killed immediately by TRAIL, acquires resistance and specifically grows out. 24 However, we could not detect any TRAIL expression in AZT treated cells and in weakly transduced cells in general (data not shown), confirming that AZT treatment almost completely inhibited transduction, permitting only negligible levels of gene expression. These data demonstrate that LV-TRAIL-treatment induces apoptosis in P693 cells, which is both transduction-dependent and -independent.
Paracrine induction of apoptosis by membrane-bound TRAIL produced by LV-TRAIL-transduced cells To further investigate induction of apoptosis by LV-TRAIL, we transduced P693 cells and cultured them for 2 days. The cells were then plated at high or low density and apoptosis was measured after additional 2 days by staining with annexin V. At this timepoint, TRAIL expression in the transduced cells was fully active, and cells that had already died because of immediate cytotoxicity of recombinant TRAIL embedded in viral particles had been removed. Apoptosis was significantly enhanced by LV-TRAIL in the high-but not in the lowdensity settings (Figure 2a ). This indicates that LV-TRAIL-transduced cells induce apoptosis in a paracrine manner in neighboring cells, dependent on cell-cell contact. As the surface expression levels of TRAIL receptors can vary depending on cellular stress such as cytotoxic therapy or high cell densities, 33 this might influence the TRAIL sensitivity of cells cultured at different densities. Thus, we analyzed the levels of TRAIL-R1 to 4 and the cell surface of confluent and non-confluent (30 and 80% confluency) P693 cells (Figure 2b ). We found a very slight downregulation of the surface expression of TRAIL-R2 in cells cultured at higher densities, but no dramatic changes of the expression levels of all TRAIL receptors analyzed. Surface expression of the 'decoy' receptors TRAIL-R3 and TRAIL-R4 could not be detected under any circumstances. This demonstrates that modulation of TRAIL sensitivity, at least at the level of receptor surface expression, by cell density, if occurring at all, could be expected to result in less cell death at higher cell densities. To evaluate whether membrane-bound fulllength TRAIL (flTRAIL) or soluble TRAIL (sTRAIL) released from TRAIL-transduced cells by protease cleavage 34, 35 is responsible for apoptosis induction, we performed ELISA assays for detection of sTRAIL in supernatant of transduced cells using TRAIL-R2-Fc protein. The amount of sTRAIL detected in the supernatant of TRAIL expressing P693 cells was below the detection limit of the assay of 0.4 ng/ml sTRAIL (Figure 2c ). This concentration is several hundred-fold below the concentration required to induce apoptosis by recombinant TRAIL in P693 cells. These data allow to exclude other modes of apoptosis induction but paracrine stimulation of TRAIL receptors in neighboring cells by membrane-bound TRAIL expressed by LV-TRAILtransduced cells.
Transduction-independent toxicity of lentiviral preparations is mediated by membrane-bound TRAIL embedded in viral particles To investigate the percentage of transduction-independent induction of apoptosis by LV-TRAIL, we transfected the virus producing 293T cells with LV-GFP or and -R4 was analyzed by flow cytometry after surface staining using specific antibodies, a biotinylated secondary antibody and streptavidin-APC. Dead cells were excluded by propidium iodide (PI) staining. (c) One hundred microliters of culture supernatant from LV-GFP-(white bar) or LV-TRAIL-transduced (black bar) P693 cells (at least 7 days after transduction) or 100 ml of fresh medium containing 0.4-3.2 ng/ml recombinant TRAIL (rsTRAIL, gray bars) were analyzed by ELISA using TRAIL-R2-Fc and a TRAIL specific antibody.
Lentiviral TRAIL tumor therapy T Wenger et al LV-TRAIL plasmids alone or in combination with helper plasmids. The cell culture supernatant was then transferred to P693 cells and apoptosis in the donor cells was measured 24 h later. This early time point was chosen as reverse transcription and integration of lentiviruses is not completed, 36 enabling us to measure transductionindependent cell death by recombinant TRAIL present in virus particles exclusively. As expected, apoptosis in P693 cells was induced by supernatant of 293T cells transfected with LV-TRAIL and the complete set of plasmids necessary for virus production (Figure 3a) . A similar degree of apoptosis was induced with supernatant from LV-TRAIL and VSV-G transfected 293T cells whereas all other combinations of transfected plasmids had no effect on cytotoxicity of supernatant. Equal transfection efficiency of plasmids was ensured by FACS analysis of GFP expression, which was found to be 490% in the transfected 293T cells for all conditions. The reason for cytotoxicity of supernatant derived from LV-TRAIL-transfected cells solely in the presence VSV-Gexpression may be due to the toxicity of VSV-G protein.
Thus, 293T cells producing VSV-G die, thereby releasing membrane fragments and vesicles able to pass the 0.22 mm filters used for clearing. These data suggest that LV-TRAIL producing cells do indeed not release soluble TRAIL, but rather release full-length TRAIL-containing membrane fragments, vesicles and viral particles, which are responsible for the transduction-independent induction of apoptosis. This is consistent with our recent observation that only membrane-bound, but not soluble TRAIL, is associated with viral particles (Figure 1d in Wenger et al.
24
).
To quantify the amount of TRAIL present in viral particles, we performed a TRAIL ELISA with two independently prepared stocks of LV-GFP and LV-TRAIL (2-8 Â 10 4 IU/100 ml), and recombinant TRAIL protein as a standard. We detected TRAIL protein only in the LV-TRAIL stocks, at a concentration of 180-290 pg TRAIL/10 3 IU (Figure 3b ). Given a transduction efficiency of 5 Â 10 5 cells in 2 ml medium at a MOI 1, with a virus stock containing 200 pg/10 3 IU, the cells are exposed to 5 Â 10 5 IU containing 50 ng/ml TRAIL. At this concentration, TRAIL is known to induce apoptosis in P693 cells within 3 days, especially when it is present in the full-length, membrane bound form, which is a very powerful inducer of apoptosis. These data suggest that full-length TRAIL is released by LV-TRAIL packaging cells and associated with the viral particles in a sufficient amount to induce the observed transduction-independent apoptosis.
Transient growth retardation of established tumors by LV-TRAIL As LV-TRAIL induces apoptosis in cancer cells in vitro,
we investigated the antitumor effects of lentiviral TRAIL transfer in vivo. P693 cells were injected subcutaneously into nude mice to generate tumor xenografts. After 2 days, tumor nodules of approximately 50 mm 3 were detectable consisting of about 1-2 Â 10 7 cells (data not shown). Ten mice per group were injected with vehicle (PBS/BSA), LV-GFP or LV-TRAIL (1.5 Â 10 7 IU in 50 ml PBS/BSA) directly into the tumor, resulting in a MOI of approximately 1. Two mice per group were randomly chosen and killed at day 2 after virus injection and the tumors were isolated. The tumor growth in the remaining mice was monitored for additional 12 days, thereafter these animals were also killed and the tumors were isolated. As measured by calipers, the volume of control and LV-GFP-transduced tumors increased similarly, whereas LV-TRAIL caused a temporary growth inhibition of about 3 days followed by regrowth of the tumors at a rate similar to that of the controls (Figure 4) . 5 IU/ml, were analyzed for TRAIL content by ELISA assay. Recombinant TRAIL (400-6400 ng/ml) was used as a standard. TRAIL content was normalized to the virus titer.
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Statistical analysis was carried out for all data acquired, but revealed a significant difference only on day 5 posttransduction. However, a long-lasting antitumor effect of LV-TRAIL was not observed. These data demonstrate that LV-TRAIL is capable of inducing a short-term growth delay in established tumors, but does not lead to long-term effects.
Analysis of tumor transduction
To analyze transduction efficiency in vivo sections of day 12 tumors were examined by fluorescence microscopy. Tumors formed by P693 cells consisted of solid, rather hard tissue, with poor vascularization in the central tumor areas. Except for central necrotic areas that could be observed at very late timepoints (mainly after more than 12 days of tumor growth in preliminary experiments), these tumors appeared to be homogeneous, devoid of any cavities, hollows or cell-free matrix regions (data not shown). In LV-GFP-transduced tumors, we found detectable GFP expression throughout the whole section, indicating efficient in vivo intratumoral gene transfer ( Figure 5 ). LV-TRAIL-transduced tumors, in contrast, showed much weaker overall transduction. Furthermore, whereas in LV-GFP-transduced samples the transduced cells were homogenously distributed in the tumor sections, LV-TRAIL-transduced cells were strongly clustered to only 3-4 clusters per tumor section (data not shown). These data indicate that even though lentiviral transduction of established tumors results in efficient gene transfer when transducing a non-toxic gene like GFP, TRAIL gene transfer was largely inefficient.
As suggested by our in vitro studies, the most likely underlying reason for the weak transduction efficiency of LV-TRAIL is non-transduction-specific apoptosis induced in TRAIL-lentivirus exposed cells, thereby preventing efficient transduction. To examine this issue, we analyzed tumor samples isolated at day 2 after injection of lentiviral vectors as at this early time point transduction is not completed and proteins of transgenes may largely result from protein carryover. 36 As expected, expression of GFP was quite low in LV-GFP-injected tumors as it results most likely from protein carryover and neither TRAIL nor apoptotic cells were detectable. This was examined by autofluorescence of GFP, or by the use of specific TRAIL or cleaved cytokeratin-18 antibodies and fluorescence microscopy ( Figure 6 ). In LV-TRAIL-treated tumors however, large areas of apoptosis, which overlapped with weak GFP fluorescence, could be detected. In consecutive sections of the same area, TRAIL protein was present in the GFP-positive areas. These results suggest that TRAIL protein present in viral particles strongly induces apoptosis in tumor cells because of high local concentrations at the injection site. This might prevent transduction, transgene expression and paracrine apoptosis induction by membrane-bound TRAIL. This is in contrast to the in vitro situation, where the viral particles are more evenly distributed throughout the cell population, leading to less apoptosis induction and comparably higher transduction rates, which in turn lead to more paracrine apoptosis. In consequence, although intratumoral lentiviral gene transfer is efficient when using an non-toxic transgene such as GFP, lentiviral gene transfer of proapoptotic molecules may be not suitable for in vivo application.
Discussion
Here, we describe the application of lentiviral TRAIL for the therapeutic induction of apoptosis in human lung cancer cells. Similar recent approaches with adenoviralor AAV-mediated TRAIL delivery by intratumoral application of the vectors have shown to suppress tumor growth in vivo. [15] [16] [17] However, adenoviral or AAV vectors mediate only transient gene expression, resulting in the outgrowth of tumors after loss of transgene expression in most cases. To overcome this obstacle we established a lentiviral expression system, which is capable of long-term and stable expression of transgenes. To circumvent the critical problem of second cancer induced by random retroviral insertion, we intended to couple this system after successful establishment to a suicide gene such as hsv-tk to destroy transduced cells after complete tumor eradication. Using lentiviral transduction of TRAIL we could induce efficient in vitro apoptosis in an established lung cancer cell line. However, cell death was only partially dependent on lentiviral transduction as TRAIL protein produced by 293T producer cells was embedded in viral particles, resulting in transduction-independent cell death. This is in line with previous observations demonstrating that enveloped viruses with CD95-L or TRAIL transgenes carry these proteins on their surface, as a result from protein expression in the packaging cells. 24, 37 Unfortunately, our attempt to further characterize this transduction-independent induction of cell death by AZT, an inhibitor of reverse transcriptase, was hampered, as this substance sensitizes for TRAIL-induced apoptosis (own observation, compare also Ghosh et al.
32
). Also, cells treated with AZT or ddC at concentrations required for inhibition of transduction underwent growth arrest after 5-7 days of culture (own data, not shown). Further analysis of transduction-dependent apoptosis 4 days after TRAIL gene transfer revealed that apoptosis occurred specifically in TRAIL transduced cells and was dependent on cell-cell contact. ELISA analysis of the culture supernatant of TRAIL transduced cells demonstrated the absence of relevant amounts of TRAIL protein, the detection limit of the assay being far below the level of TRAIL protein needed for killing activity on the cells used. Thus, we conclude that apoptosis was induced in a paracrine manner by membrane-bound TRAIL. This result corresponds to previous publications characterizing the bystander effect of virally expressed TRAIL, 16 or describing that the production of relevant amounts of sTRAIL by mammalian cells involves secretion of sTRAIL from intracellular stores, 38, 39 rather than shedding of the extracellular domain of TRAIL present on the plasma membrane. The analysis of TRAIL receptor expression revealed high surface levels of TRAIL-R2 and lower, but still readily detectable levels of TRAIL-R1, at all culture conditions tested. RNA expression profiling of these cells (termed ELCC in that report) 40 revealed the upregulation of TRAIL-R3 in a cisplatin-resistant derived cell line. In our setting, however, we could not observe cell surface expression of the TRAIL decoy receptors TRAIL-R3 and -R4, in any of the culture conditions used.
Concluded from our additional experiments, transduction-independent cell death upon lentiviral TRAIL treatment may have been rather induced by full-length TRAIL protein embedded in viral particles, which could not been removed from viral supernatant. Thus, upon expression of the cytotoxic envelope protein VSV-G or the production of complete viral particles, a killing activity in the supernatants could be detected. In the case of VSV-G expression, cellular debris, membrane fragments and vesicles are released from dying packaging cells. Therefore, the killing activity present in lentiviral TRAIL preparations was most likely mediated by TRAIL bound to membrane vesicles released by packaging cells undergoing cell death.
In an attempt to utilize the proapoptotic properties of LV-TRAIL in a therapeutic setting, we transduced an established lung tumor cell line xenografted to nude mice. We used a virus dose resulting in a MOI similar to the one used in vitro, and avoided huge virus doses that may be unrealistic for a future use in patients. Intratumoral injection of lentiviral TRAIL resulted in growth suppression, which was, however, only transient. Analysis of the tumors revealed widespread expression of GFP when using the lentiviral GFP control construct. As the P693 tumors consisted of homogeneous, hard, poorly vascularized tissue, an even or complete transduction pattern of the tumor would be unrealistic to expect. The GFP expression achieved upon transduction, and the absence of larger amounts of blood vessels in the center of the tumor demonstrate that direct intratumoral injection is a useful route of administration, possibly superior when compared to other possibilities such as injection into blood vessels. In contrast, the TRAIL-transduced tumors exhibited much weaker and clustered GFP expression. As apoptosis induction can be expected to take place preferentially in the areas of contact between transduced and non-transduced cells, this pattern and the much lower overall transduction can explain the lack of long-term effects. Such differences in transduction pattern between control and transgene constructs have so far scarcely been observed. Further analysis of tumors isolated shortly after transduction revealed that the transduction-independent effects of LV-TRAIL application overcame the beneficial transduction-dependent effects. TRAIL protein embedded in the viral particles strongly induced apoptosis in cells near the injection sites. As cells having contact with the viral particles were preferentially killed and were not available for transduction anymore, the overall transduction rates dropped sharply, leading to the observed lack of long-term effects. Although we used equal MOIs for in vitro and in vivo experiments, different effects were observed in cell culture and animal studies. The underlying reason may be that the virus and the associated TRAIL protein is diluted in medium in vitro, resulting in lower direct apoptosis induction by the viral particle and subsequently better transduction rates using lentiviral TRAIL. The observation of transduction-and cell-cell-contact-dependent, paracrine apoptosis induction in vitro was made by replating of the surviving cells (and thus removing dead cells) 2 days post-transduction and two additional days of culture. In vivo however, the virus is delivered as a more concentrated suspension into a confined area. Owing to the particle size of approximately 100 mm, the virus particles cannot quickly diffuse through the tumor, creating a high local concentration of particles and TRAIL protein. This leads to the strong induction of cell death at this site, preventing efficient transduction. Thus, TRAIL surface expression could have occurred only in the few successfully transduced areas of the tumor, leading to insuficient contact of transduced cells with surrounding cells, and subsequently to insufficient paracrine apoptosis induction. Even though this might not occur at lower virus doses, the MOI used in our experiments is necessary for efficient tumor transduction, as judged by the GFP expression obtained with the control construct. Raising the dose of viral particles would most likely only lead to more immediate induction of apoptosis, but not to a better transduction rate.
We also cannot rule out that upon transduction in vivo, the TRAIL expressing cells become resistant and grow out because of intracellular retention of TRAIL receptors. We have observed and recently described this phenomenon several cancer cell lines, 24 the P693 cells among them. This phenomenon would also in part explain the observed transduction patterns in TRAIL-transduced P693 tumors. Whereas the overall transduction was much weaker in these tumors compared to GFP transduced control tumors, the few transduced areas were larger homogeneously GFP expressing. This might be because of one or more cells, which became successfully transduced, were thus rendered resistant and grew out locally. As apoptosis induction in non-transduced cells could then only occur at the border of the transduced and nontransduced zones, this would, especially in the fastgrowing xenograft model used here and at the weak apparent transduction rate, not be sufficient to slow tumor growth.
The outgrowth of transduced cells, ultimately resulting in a homogeneous or at least a strongly enriched transgene containing tumor cell population, could be used to overcome the weak in vivo transduction rate, a main obstacle of cancer gene therapy using suicide genes. [10] [11] [12] [13] [14] By co-expression of TRAIL and a classical suicide gene, prodrug mediated apoptosis induction after outgrowth of the transduced cells would allow the efficient elimination of tumor cells. However, because the protein carryover in the viral particles caused by constitutive TRAIL expression in the packaging cells, this approach is impossible using the system described.
In conclusion, for efficient expression of lentiviral TRAIL in tumor cells for therapeutic purposes, approaches to minimize transduction-independent cell death are needed. This might be achieved by regulated or tumor-specific expression systems, or by transduction in the presence of apoptosis-inhibiting compounds. Proapoptotic gene therapy relying on the use of such compounds is, however, not likely to be a feasible therapeutic approach. Our studies show that lentiviral TRAIL gene transfer is an effective way to induce apoptosis in cancer cells in vitro. The therapeutic application is impeded by effects occurring also, albeit to a much lower degree, in vitro, but having a far more dramatic role in vivo. Thus, for therapeutic intervention, the lentiviral expression system may be not suited for direct overexpression of TRAIL in tumor cells but rather for overexpression of TRAIL in resistant, non-malignant cells such as T cells, stem cells, tumor stromal cells or endothelial cells, to achieve paracrine induction of apoptosis in neighboring tumor cells.
